

ENVOY CAPITAL GROUP INC.

Form 6-K

October 18, 2011

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16 OF  
THE SECURITIES EXCHANGE ACT OF 1934**

As at **October, 2011**

Commission File No. **00-30082**

**ENVOY CAPITAL GROUP INC.**

(Translation of registrant's name into English)

**30 St. Patrick Street, Suite 301**

**Toronto, Ontario M5T 3A3**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

**Form 20-F**  **Form 40-F**

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1)

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7)

Indicate by check mark whether the registrant, by furnishing the information contained in this Form, is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

---

**SUBMITTED HEREWITH**

<b>Exhibits</b>	
<u>99.1</u>	<u>News Release dated October 11, 2011 - Envoy Capital Announces Proposed Acquisition of Merus Labs International</u>
<u>99.2</u>	<u>Material Change Report dated October 11, 2011</u>
<u>99.3</u>	<u>Material Document: Letter of Intent to Merus Labs International Inc. dated October 11, 2011</u>
<u>99.4</u>	<u>Notice of meeting and record date</u>

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: October 14, 2011

**ENVOY CAPITAL GROUP INC.**

*/s/ Andrew Patient*

---

Andrew Patient  
Chief Financial Officer

---